

**Norway-Oslo: Influenza vaccines**  
**OJ S 12/2022 18/01/2022**  
**Contract award notice**  
**Supplies**

**Legal Basis:**

Directive 2014/24/EU

---

**Section I: Contracting authority**

**I.1. Name and addresses**

Official name: Folkehelseinstituttet

National registration number: 983 744 516

Postal address: Postboks 222 Skøyen

Town: OSLO

NUTS code: NO Norge

Postal code: 0213

Country: Norway

Contact person: Ole Andreas Fuglesang

E-mail: [ole.andreas.fuglesang@fhi.no](mailto:ole.andreas.fuglesang@fhi.no)

Telephone: +47 21076629

**Internet address(es):**

Main address: <http://www.fhi.no>

Address of the buyer profile: <https://eu.eu-supply.com/ctm/Company/CompanyInformation/Index/346372>

**I.4. Type of the contracting authority**

Ministry or any other national or federal authority, including their regional or local subdivisions

**I.5. Main activity**

Health

---

**Section II: Object**

**II.1. Scope of the procurement**

**II.1.1. Title**

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023

Reference number: 21/16624

**II.1.2. Main CPV code**

33651660 Influenza vaccines

**II.1.3. Type of contract**

Supplies

**II.1.4. Short description**

Folkehelseinstituttet [the Norwegian Institute of Public Health] has held an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups for the seasons 2022

/2023. Two sub-contracts have been entered into, where total contract volume is distributed 60% to service provider no. 1 and 40% to service provider no. 2.

#### **II.1.6. Information about lots**

This contract is divided into lots: yes

#### **II.1.7. Total value of the procurement**

Value excluding VAT: 98 000 000,00 NOK

### **II.2. Description**

#### **II.2.1. Title**

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023 - 60% of total contract volume

Lot No: 1

#### **II.2.2. Additional CPV code(s)**

33651660 Influenza vaccines

#### **II.2.3. Place of performance**

NUTS code: NO Norge

Main site or place of performance: Oslo

#### **II.2.4. Description of the procurement**

Folkehelseinstituttet [the Norwegian Institute of Public Health] has held an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition was the lowest price. The tender documentation had several minimum requirements for the vaccination. All the minimum requirements must be fulfilled.

The procurement was carried out in accordance with the Public Procurement Act (PPA) of 17 June 2016 and the Public Procurement Regulations (PPR) part I and part III of 12 August 2016. Contract award was done in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

Prior to announcement of the contest, the Norwegian Institute of Public Health received signals that there would be significant risk that doses could not be allocated to Norway if the procurement process was not carried out before the middle of December. As the Norwegian Institute of Public Health could not risk Norway being left without doses, it was decided to hold the contest with a 15 day tender deadline. Incidentally, the procurement was carried out in-line with the procurement regulations.

The total contract volume was previously estimated at 700,000 - 900,000 doses

In this contest, in consideration of preparedness, the Norwegian Institute of Public Health awarded two sub-contracts where the total volume is divided as follows:

60% of total volume, 516,000 doses, Sanofi Aventis Norge AS

40% of total volume, 344 000 doses, Viatrix AS

The award was done in-line with the Tender Documentation Chapter 6 'Award Criteria' and sub-points.

First delivery in the new contract is anticipated to be before 20 September 2022.

#### **II.2.5. Award criteria**

Price

#### **II.2.11. Information about options**

Options: no

#### **II.2.13. Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds:  
no

#### **II.2.14. Additional information**

Clarification concerning point II.1.7) Total Value of the Procurement:

The Norwegian Institute of Public Health had previously estimated this total value for the entire procurement based on publicly accessible information about the AIP of relevant vaccines.

### **II.2. Description**

#### **II.2.1. Title**

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023 - 40% of total contract volume

Lot No: 2

#### **II.2.2. Additional CPV code(s)**

33651660 Influenza vaccines

#### **II.2.3. Place of performance**

NUTS code: NO Norge

Main site or place of performance: Oslo

#### **II.2.4. Description of the procurement**

Folkehelseinstituttet [the Norwegian Institute of Public Health] has held an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition was the lowest price. The tender documentation had several minimum requirements for the vaccination. All the minimum requirements must be fulfilled.

The procurement was carried out in accordance with the Public Procurement Act (PPA) of 17 June 2016 and the Public Procurement Regulations (PPR) part I and part III of 12 August 2016. Contract award was done in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

Prior to announcement of the contest, the Norwegian Institute of Public Health received signals that there would be significant risk that doses could not be allocated to Norway if the

procurement process was not carried out before the middle of December. As the Norwegian Institute of Public Health could not risk Norway being left without doses, it was decided to hold the contest with a 15 day tender deadline. Incidentally, the procurement was carried out in-line with the procurement regulations.

The total contract volume was previously estimated at 700,000 - 900,000 doses

In this contest, in consideration of preparedness, the Norwegian Institute of Public Health awarded two sub-contracts where the total volume is divided as follows:

60% of total volume, 516,000 doses, Sanofi Aventis Norge AS

40% of total volume, 344 000 doses, Viatris AS

The award was done in-line with the Tender Documentation Chapter 6 'Award Criteria' and sub-points.

First delivery in the new contract is anticipated to be before 20 September 2022.

#### **II.2.5. Award criteria**

Price

#### **II.2.11. Information about options**

Options: no

#### **II.2.13. Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds:  
no

#### **II.2.14. Additional information**

Clarification concerning point II.1.7) Total Value of the Procurement:

The Norwegian Institute of Public Health had previously estimated this total value for the entire procurement based on publicly accessible information about the AIP of relevant vaccines.

### **Section IV: Procedure**

---

#### **IV.1. Description**

##### **IV.1.1. Type of procedure**

Open procedureAccelerated procedureJustification:

Prior to announcement of the contest, the Norwegian Institute of Public Health had received signals that there would be significant risk that doses could not be allocated to Norway if the procurement process was not carried out before the middle of December. As the Norwegian Institute of Public Health could risk Norway being left without doses, it was decided to hold a contest with a 15 day tender deadline.

##### **IV.1.3. Information about a framework agreement or a dynamic purchasing system**

##### **IV.1.8. Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

#### **IV.2. Administrative information**

##### **IV.2.1. Previous publication concerning this procedure**

Notice number in the OJ S: [2021/S 222-585824](#)

##### **IV.2.8. Information about termination of dynamic purchasing system**

##### **IV.2.9. Information about termination of call for competition in the form of a prior information notice**

## Section V: Award of contract

---

**Contract No:** 1

**Lot No:** 1

**Title:**

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023 - 60% of total contract volume

A contract/lot is awarded: yes

### V.2. Award of contract

#### V.2.1. Date of conclusion of the contract

30/12/2021

#### V.2.2. Information about tenders

Number of tenders received: 3

Number of tenders received from tenderers from other EU Member States: 3

Number of tenders received by electronic means: 3

The contract has been awarded to a group of economic operators: no

#### V.2.3. Name and address of the contractor

Official name: SANOFI-AVENTIS NORGE AS

National registration number: 976 335 147

Postal address: Professor Kohtsvei 5-17

Town: Lysaker

NUTS code: NO Norge

Postal code: 1325

Country: Norway

E-mail: [Britt.Moe@sanofi.com](mailto:Britt.Moe@sanofi.com)

The contractor is an SME: no

#### V.2.4. Information on value of the contract/lot

Initial estimated total value of the contract/lot: 58 800 000,00 NOK

Total value of the contract/lot: 1,00 NOK

#### V.2.5. Information about subcontracting

## Section V: Award of contract

---

**Contract No:** 2

**Lot No:** 1

**Title:**

Four valent vaccine against seasonal influenza - Supplementary volume for the season 2022 /2023 - 40% of total contract volume

A contract/lot is awarded: yes

### V.2. Award of contract

**V.2.1. Date of conclusion of the contract**

30/12/2021

**V.2.2. Information about tenders**

Number of tenders received: 3

Number of tenders received from tenderers from other EU Member States: 3

Number of tenders received by electronic means: 3

The contract has been awarded to a group of economic operators: no

**V.2.3. Name and address of the contractor**

Official name: Viatris AS

National registration number: 914158877

Postal address: Hagaløkkveien 26

Town: Asker

NUTS code: NO Norge

Postal code: 1371

Country: Norway

E-mail: [rolf.kjolstad@viatris.com](mailto:rolf.kjolstad@viatris.com)

Telephone: +47 91316761

The contractor is an SME: no

**V.2.4. Information on value of the contract/lot**

Initial estimated total value of the contract/lot: 39 200 000,00 NOK

Total value of the contract/lot: 1,00 NOK

**V.2.5. Information about subcontracting****Section VI: Complementary information**

---

**VI.3. Additional information**

On the following basis, the real contract value for each sub-contract is not given in the notice: Price per dose is the only price element in the contest. The Norwegian Institute of Public Health has determined that pursuant to the Freedom of Information Act §13 and the Public Administration Act §13 first paragraph point 2), unit prices (price per dose) is information of competitive importance to keep confidential from the tenderers who could be awarded sub-contracts, and that the information is thereby subject to confidentiality. If the real value of the sub-contracts was stated, it would be possible to derive unit prices using information on the number of doses.

The Norwegian Institute of Public Health states that the combined value of both sub-contracts is significantly lower than the previously estimated procurement total value (point II.1.7 the Procurement's total value). The value of each sub-contract is over the EEA threshold.

**VI.4. Procedures for review****VI.4.1. Review body**

Official name: Oslo tingrett

Postal address: Postboks 2106 Vika

Town: Oslo

Postal code: 0125

Country: Norway

E-mail: [oslo.tingrett@domstol.no](mailto:oslo.tingrett@domstol.no)

Telephone: +47 22035200

**VI.5. Date of dispatch of this notice**  
13/01/2022